Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
A minimalist representation of a pill and a molecule symbolizing drug discovery.

Jun 3, 2026

Nxera Pharma: Obesity pipeline advances, commercial growth, and AI-driven discovery fuel strategic momentum

Nxera Pharma is making notable strides in its obesity and rare disease pipelines, showcasing advancements in novel oral small molecules and the potential for out-licensing key assets.The company's commercial growth is particularly evident in Japan, where they have achieved significant milestone income. This success is bolstered by the introduction of a new AI-driven drug discovery platform, which is integral to their strategy aimed at specialty and rare diseases.This momentum reflects Nxera's co
A biological data model on a lab table with research equipment in the background.

Jun 3, 2026

Ingenix raises €13m to scale AI drug development engine

Ingenix has successfully secured €13 million in funding to enhance its AI-driven drug development capabilities, building on a previous €9 million seed round. This investment aims to expand the company's Biological Reasoning Engine, a sophisticated AI tool designed to facilitate translational and clinical research decisions, while also increasing collaboration opportunities with pharmaceutical and biotech partners.Founded in 2023, Ingenix is pioneering an innovative approach known as Modality Fus
A test tube with a liquid sample on a lab countertop

Jun 3, 2026

Exclusive: Apoha, startup pioneering AI based on liquid 'wave form' data, debuts with $36 million

Apoha, a pioneering startup in AI-driven material science, has emerged from stealth with $36 million in funding to develop innovative substances based on unique liquid wave form data.The funding comprises a seed round from 2024 and a recent unlettered round, led by Singular, with support from other venture firms and a grant from Innovate UK. Apoha aims to leverage a novel type of data—wave forms generated by materials in liquid under external forces—to enhance the creation and modification of va
Flat illustration of a computer chip representing data analytics in drug development.

Jun 3, 2026

Evotec Appoints Rui Wang as Head of Global In Silico and AI

Evotec has appointed Rui Wang as the new Executive Vice President, Head of Global In Silico and AI, marking a significant step in enhancing its AI-driven research and development capabilities.With over two decades of experience in the pharmaceutical and biotechnology sectors, Wang will lead efforts to integrate data analytics and AI throughout Evotec's R&D processes. His previous role at AstraZeneca involved overseeing data and AI initiatives, equipping him with the expertise to drive innovation
A minimalist representation of a drug compound molecule in flat design.

Jun 3, 2026

Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026 - News and Statistics

The competition between Recursion Pharmaceuticals and Schrodinger highlights distinct drug discovery strategies as they leverage technology and data in their operations.Recursion Pharmaceuticals focuses on mechanizing drug discovery through artificial intelligence and extensive data analysis within the biotech sector. The company collaborates with major industry players like Roche and Bayer, relying heavily on their partnerships for revenue. Despite reporting a revenue increase of 26.9% to appro
A supercomputer in a research lab with NVIDIA GPUs

Jun 2, 2026

Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia

The integration of artificial intelligence (AI) within the pharmaceutical industry is rapidly evolving, yet the gap between investment and tangible outcomes remains significant, particularly in Asia.Recent developments highlight the growing conviction that AI is essential infrastructure in drug research and development. For instance, Eli Lilly's launch of the "LillyPod," a supercomputer equipped with over 1,000 NVIDIA GPUs, symbolizes this trend. However, despite such advancements, the company a
A minimalist illustration of a pill and tablet on a solid background.

Jun 2, 2026

BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform

BullFrog AI has announced the formation of a new commercial leadership team aimed at accelerating growth for its integrated pharmaceutical AI platform.The newly appointed team consists of seasoned executives with extensive backgrounds in enterprise IT solutions, drug discovery, and advanced therapy platforms. Their collective expertise is expected to enhance BullFrog AI's commercial strategy and expand its pipeline for AI-driven solutions, including products like bfPREP, bfLEAP, and bfARENAS. Th
A glass vial filled with liquid on a lab bench in a dimly lit laboratory.

Jun 2, 2026

Veteran tech and biotech execs join BullFrog AI to push drug discovery

BullFrog AI has announced the formation of a new commercial leadership team aimed at driving growth for its AI-driven drug discovery platform.The company, based in Gaithersburg, Maryland, is leveraging the expertise of seasoned executives to enhance its commercial strategy and expand its market presence. The newly appointed leaders include John Stewart as SVP of Commercial Sales, Eric Roos as SVP of Business Development & Corporate Strategy, and Tom Hazel, Ph.D., as VP of Scientific Operations.
A minimalist representation of a drug compound and AI integration in biotech.

Jun 2, 2026

Rakovina’s Rx: AI and Austerity Fuel a Biotech Turnaround

Rakovina Therapeutics has successfully navigated a financial turnaround by integrating AI into its drug discovery process while implementing stringent cost controls.In its recent financial report for Q1 2026, Rakovina Therapeutics showcased a notable strategic shift, merging financial austerity with a robust investment in AI-driven drug discovery. This pivot has stabilized the company, improving its balance sheet and operational efficiency. The firm reported a 23% reduction in net loss, alongsid
A test tube in a laboratory setting

Jun 1, 2026

Q1 2026: When Pharma AI Partnerships Crossed a Threshold

The first quarter of 2026 marked a pivotal moment for artificial intelligence in the pharmaceutical sector, characterized not just by an increase in partnerships, but by a fundamental shift in how these collaborations are structured and integrated into the industry.In Q1 2026, the number of significant AI partnerships doubled to thirty-six compared to the same period in 2025. However, the real significance lies in the nature of these deals. They reflect a transition from experimental pilot proje
A close-up of a cell culture dish in a lab setting, with a pipette above it.

May 28, 2026

Pamela Carroll ’85 uses AI in biotechnology to tackle formerly “undruggable” drivers of disease

Pamela Carroll, a 1985 graduate of Saint Michael’s College, is pioneering the integration of artificial intelligence (AI) in biotechnology, focusing on previously "undruggable" disease drivers. Her career trajectory, which includes significant roles in both research and business, highlights the transformative potential of AI in drug discovery and development.Carroll's journey began at the National Cancer Institute, where her fascination with cell biology took root. This interest propelled her th
A test tube with protein solution in a dimly lit lab

May 28, 2026

Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications

Sino Biological's innovative cell-free protein synthesis technology has been pivotal in a recent study conducted by Tencent AI for Life Sciences Lab, as published in *Nature Communications*. This collaboration highlights the integration of AI in protein design, enabling the rapid validation of proteins that exhibit enhanced activity, stability, and multifunctionality.The study addresses a significant challenge in protein engineering: the transition from AI-generated amino acid sequences to funct